Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Tools for Decision Making Sections
Author Bio
Introduction
Part I
Part II
Age and Co-morbidity
Currently selected section: Screening in the Elderly
Case Study 3: Patient Histories

Estimating Life Expectancy

Approach to Screen Decisions
Calculating the Impact of Co-morbid Illness
Adjusting Life Expectancy
References


Chapter 14: Tools for Decision Making: Principles of Screening in the Elderly
        

The key to screening decisions is estimating potential benefit relative to harms and costs.

Key Principles of Screening
  • Benefits accrue only to individuals who have the sought-for disease.
  • Harms and costs can affect every person screened.
  • Therefore, the benefits of screening a population increase relative to harms as the prevalence of the disease increases.

Since the risk of many diseases increases with age, it would initially appear that the elderly should benefit more than younger people from screening. However, other consequences of advancing age reduce the benefit of screening in the elderly. The most important is chronic disease.

Anyone can die of other diseases before experiencing the benefit of screening, but this problem is much worse for the elderly because so many have chronic, ultimately fatal, disease. This leads to a key principle of screening in the elderly:

Key Principles of Screening

Many older people undergo screening for a disease that they might have, and then die of a disease that they do have before screening could possibly help them.

Clinical trials of screening often show that the screened group and the control group die at the same rate for at least 5 years. For example, the table below shows the delay in benefit for three common screening procedures.

Table 3.2.1: Time between initiating screening and observing a reduction in disease-specific mortality
Screening Test Time to benefit Reference
Mammography 5 years Lancet.1993;341:973-78
Fecal-occult blood 5 years NEJM.1993;328:1365-71
Serum cholesterol 2-5 years BMJ.1994;308:367-73


The harms of screening, follow-up testing, and subsequent treatment increase for the elderly for several reasons:

  • The hardship of undergoing a screening test, follow-up testing ,and treatment is greater for the elderly due to:
    • Physical and cognitive limitations
    • Problems getting transportation
    • Difficulty adhering to the preparations required for some tests

  • These harms and burdens are more immediate, and more certain, than the benefits.

Therefore, many patients will view the balance between benefit and harm as shifting towards net harm.

For older individuals, the decision about who will benefit from a screening test depends on the ability to estimate life expectancy. Therefore, the methods used to determine life expectancy are of crucial importance, and are addressed in sections that follow.


Page 34 of 43
      Previous Section